| Previous Close | 65.950 |
| Open | 66.070 |
| Bid | 65.750 x 2300 |
| Ask | 65.760 x 1900 |
| Day's Range | 65.200 - 66.310 |
| 52 Week Range | 58.290 - 66.800 |
| Volume | 6,684,882 |
| Avg. Volume | 8,044,384 |
| Market Cap | 179.31B |
| Beta | 0.94 |
| PE Ratio (TTM) | 35.60 |
| EPS (TTM) | 1.85 |
| Earnings Date | Oct 27, 2017 |
| Dividend & Yield | 1.88 (2.84%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | 70.00 |
- CNW Group•3 hours ago
New First Line Treatment Now Available for Canadians with Metastatic Non-Small Cell Lung Cancer
New First Line Treatment Now Available for Canadians with Metastatic Non-Small Cell Lung Cancer
- Business Wire•yesterday
Pro Baseball Hall of Famer and Cancer Survivor Mike Schmidt Joins Merck, Jim Kelly and Leading Cancer Organizations To Expand Your Cancer Game Plan To Help More People Impacted by Cancer
Pro Football Hall of Famer Jim Kelly and Pro Baseball Hall of Famer Mike Schmidt – two legendary athletes whose determination, faith and hard work earned them a place in sports history – now have something else in common: overcoming cancer.
- InvestorPlace•2 days ago
Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear
Bristol-Myers Squibb Co (NYSE:BMY) stock has had a tumultuous 12-month period. In January, it fell 20% but luckily for the bulls it recovered all of it within five weeks. Since then and after several +/-8% moves, BMY is up 12% in 52 weeks which is decent but still underwhelming relative to the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) as a whole.Source: A 4 via Flickr
